More color on Cepheid Q1 results


Total top line sales were $106.9M, up 16% yoy. Clinical Systems revenues were $17.3M (+38%) and Clinical Reagents revenues were $83.1M (+24%).

The North America business fell slightly (-1%) while the International business grew 56%.

Net loss was -$0.13/share compared to breakeven a year ago.

503 GeneXpert systems placed globally.

GAAP gross margin was 50% compared to 53% yoy.

2014 guidance range for revenues is $446M - $461M with a loss/share between -$0.38 and -$0.43.

(CPHD +0.7%)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs